February 2026 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
February 2026 in “Skin Appendage Disorders” Scalp microinfusion with dutasteride is a safe and promising treatment for male hair loss.
February 2026 in “PubMed” PRP-based treatments can increase hair density, but results vary among individuals.
January 2026 in “Dermatologic Therapy” Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.
November 2025 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
October 2025 in “EMJ Dermatology” GLP-1RA therapy may increase the risk of hair loss.
September 2025 in “Journal of the American Academy of Dermatology” Eyebrow and eyelash hair loss in alopecia areata worsens quality of life.
July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
June 2025 in “Pharmaceuticals” Finasteride use may increase suicidality risk, especially in young men.
November 2024 in “Journal of the American Academy of Dermatology”
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
December 2023 in “Acta dermato-venereologica” Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.
December 2023 in “Dermatology and therapy” Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.
October 2023 in “Frontiers in medicine” Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
December 2022 in “International Journal of Research in Dermatology” Growth factor concentrate therapy helps manage hair loss.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated ashy dermatosis in a patient.
22 citations
,
February 2023 in “European Journal of Neurology” Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Higher monocyte counts may predict poor response to adalimumab in hidradenitis suppurativa patients.
2 citations
,
December 2017 in “Korean Journal of Medicinal Crop Science” Houttuynia cordata extract promotes hair growth and could be useful in hair care products.
1 citations
,
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib effectively regrows hair in severe alopecia areata, especially in adolescents.
1 citations
,
September 2025 in “Eye” Certain drugs can cause eyelid inflammation, so doctors should monitor and educate patients on eyelid care.
1 citations
,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
These medications for BPH have known risks and may have new side effects.
These medications for BPH have known risks and may have new side effects.
January 2026 in “EJC Skin Cancer” The serum effectively improves hair growth and is well-tolerated for post-cancer hair loss.
December 2025 in “JMIR Dermatology” Topical finasteride is well-tolerated and satisfies most users with minimal side effects.
Most patients were satisfied with topical finasteride, and few experienced side effects.
Wasabi leaf extract affects gene expression in skin cells.